Blog | DRL US

Patient-Derived Tumor Organoids

May 14, 2026

Patient-DerivedTumor Organoids What the Science Shows — and Why Preclinical Teams Are Adopting Them 01 The Model Fidelity Problem Immortalized cell lines have drifted genetically from their source tumors. PDX…

Leleka BIO Predictive Oncology Platform

June 30, 2025

DRL is introducing Leleka BIO™ Predictive R&D Intelligence Predict clinical success before the first patient is dosed. Leleka BIO™ turns living patient tumors and multi-omics data into an AI “digital…

Innovative Initiatives of DRL

December 18, 2024

Innovative Initiatives of DRL Excited to share that #DRL is at the forefront of advancing biomedical research through two innovative initiatives: 1. Expansion of primary-derived cell lines with custom immortalization services. We're…

The Advantages of Using Primary Derived Cancer Cell Lines in Drug Discovery

July 11, 2024

The Advantages of Using Primary Derived Cancer Cell Lines in Drug Discovery In the rapidly evolving field of drug discovery, choosing the right cell model is crucial for developing effective cancer treatments.…

The Transformative Role of Artificial Intelligence in Cancer Diagnosis and Biospecimen Analysis

May 8, 2024

The Transformative Role of Artificial Intelligence in Cancer Diagnosis and Biospecimen Analysis Artificial intelligence (AI) has emerged as a pivotal tool in revolutionizing cancer diagnosis and biospecimen analysis. This article…